Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes

Diabetes

Volumn 48, Issue 2, 1999, Pages 241-253

  Kahn, Steven E ^a,b   Andrikopoulos, Sofianos ^b   Verchere, C Bruce ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID;

FAT INTAKE; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0032969276     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.2.241     Document Type: Review

References (119)

1. Opie E: The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islets of Langerhans. J Exp Med 5:527-540, 1901
2. Bell ET: Hyalinization of the islets of Langerhans in nondiabetic individuals. Am J Pathol 35:801-805, 1959
3. Westermark P: Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 77:91-94, 1972
4. Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH, Turner RC: Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285-289, 1990
5. Glenner GG: Amyloid deposits and amyloidosis: the beta-fibrilloses. N Engl J Med 302:1283-1292, 1333-1343, 1980
6. Falk RH, Comenzo RL, Skinner M: The systemic amyloidoses. N Engl J Med 337:898-909, 1997
7. Glenner GG, Wong CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-890, 1984
8. WHO-IUIS Nomenclature Sub-Committee: Nomenclature of amyloid and amyloidosis. Bull World Health Organ 71:105-112, 1993
9. Kisilevsky R, Fraser PE: Aβ amyloidogenesis: unique, or variation on a systemic theme? Crit Rev Biochem Mol Biol 32:361-104, 1997
10. Meyer JS: Fine structure of two amyloid-forming medullary carcinomas of thyroid. Cancer 21:406-425, 1968
11. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJS, Holman RR, Turner RC: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151-159, 1988
12. Berger G, Berger N, Guillaud MH, Trouillas J, Vauzelle JL: Calcitonin-like immunoreactivity of amyloid fibrils in medullary thyroid carcinomas: an immunoelectron microscope study. Virchows Arch A Pathol Anat Histopathol 412:543-551, 1988
13. Westermark P, Wernstedt C, O'Brien TD, Hayden DW, Johnson KH: Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol 127:414-417, 1987
14. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islets. Proc Natl Acad Sci U S A 84:3881-3885, 1987
15. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 184:8628-8632, 1987
16. Coria F, Castano E, Prelli F, Larrondo-Lillo M, van Duinen S, Shelanski ML, Frangione B: Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 58:454-458, 1988
17. McGeer PL, Akiyama H, Itagaki S, McGeer EG: Immune system response in Alzheimer's disease. Can J Neurol Sci 16:516-527, 1989
18. Wisniewski T, Frangione B: Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135:235-238, 1992
19. Snow AD, Wight TN: Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging 10:481-497, 1989
20. Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, Arai M, Schreier WA, Morgan DG: An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron 12:219-234, 1994
21. Westermark P: Amyloid and polypeptide hormones: what is their relatioaship? Amyloid Int J Exp Clin Invest 1:47-60, 1994
22. Davidson MB: The effect of aging on carbohydrate metabolism: a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly. Metabolism 28:687-705, 1979
23. Clark A, de Koning EJP, Hattersley AT, Hansen BC, Yajnik CS, Poulton J: Pancreatic pathology in non-insulin dependent diabetes (NIDDM). Diabetes Res Clin Pract 28 (Suppl.):S39-S47, 1995
24. Porte D Jr, Kahn SE: Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β-cell dysfunction? Diabetes 38:1333-1336, 1989
25. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:5036-5040, 1990
26. Nishi M, Sanke T, Seino S, Eddy RL, Fan Y-S, Byers MG, Shows TB, Bell GI, Steiner DF: Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history. Mol Endocrinol 3:1775-1781, 1988
27. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr, Porte D Jr: Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39:634-638, 1990
28. Butler PC, Chou J, Carter WB, Wang Y-N, Bu B-H, Chang D, Chang J-K, Rizza RA: Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39:752-756, 1990
29. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Prager R: Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34:52-54, 1991
30. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H, Matsukara S: Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15:97-102, 1992
31. Verchere CB, Rittenhouse J, Andrikopoulos S, Koda JE, Kahn SE: Glycosylated amylin is secreted by human islets in vitro (Abstract). Diabetes 46 (Suppl. 1):357A, 1997
32. Leighton B, Cooper GJ: Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 335:632-635, 1988
33. Silvestre RA, Peiro' E, De'gano P, Miralles P, Marco J: Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul Pept 31:23-31, 1990
34. Cooper GJS: Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr Rev 15:163-201, 1994
35. Young AA, Gedulin BR, Rink TJ: Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 45:1-3, 1996
36. Kong MF, Stubbs TA, King P Macdonald IA, Lambourne JE, Blackshaw PE, Perkins AC, Tattersall RB: The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologin 41:577-583, 1998
37. Johnson KH, O'Brien TD, Betsholtz C, Westermark P: Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med 321:513-518, 1989
38. Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368:756-760, 1994
39. Janson J, Ashley R, Butler P: Human islet amyloid polypeptide (hIAPP) cytotoxicity is caused by membrane damage (Abstract). Diabetes 47 (Suppl. 1):A250, 1998
40. Fox N, Schrementi J, Nishi M, Ohagi S, Chan SJ, Heisserman JA, Westermark GT, Leckstrom A, Westermark P, Steiner DF: Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS Lett 323:4044, 1993
41. Hoppener JWM, Verheek JS, de Koning EJP, Oosterwijk C, van Hulst KL, Visser-Vernooy HJ, Hofhuis FMA, van Gaalen S, Berends MJH, Hackeng WHL, Jansz HS, Morris JK, Clark A, Capel PJA, Lips CJM: Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lark of marked hyperglycaemia and hyperinsulinaemia. Diabetologia 36:1258-1265, 1993
42. D'Alessio DA, Verchere CB, Kahn SE, Hoagland V, Baskin DG, Palmiter RD, Ensinck JW: Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:1457-1461, 1994
43. Yagui K, Yamaguchi T, Kanatsuka A, Shimada F, Huang CI, Tokuyama Y, Ohsawa H, Yamamura K, Miyazaki J, Mikata A, Yoshida S, Makino H: Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin. Eur J Endocrinol 132:487-496, 1995
44. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC: Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:7283-7288, 1996
45. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE: Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:3492-3496, 1996
46. Kane JP, Sata T, Hamilton RL, Havel RJ: Apoprotein composition of very low density lipoproteins of human serum. J Clin Invest 56:1622-1634, 1975
47. Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52:223-261, 1983
48. Brewer HB Jr, Zech LA, Gregg RE, Schwartz D, Schaefer EJ: Type III hyperlipoproteinemia diagnosis, molecular defects, pathology, and treatment. Ann Intern Med 98:623-640, 198:3
49. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923, 1993
50. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinisto L, Halonen P, Kontula K: Apolipoprotein E, dementia, and cortical deposition of beta-amyloid. N Engl J Med 333:1242-1247, 1995
51. Yamaguchi H, Ishiguro K, Sugihara S, Nakazato Y, Kawarabayashi T, Sun X, Hirai S: Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer beta-amyloid deposition. Acta Neuropathol 88:413-419, 1994
52. Charge SB, Esiri MM, Bethune CA, Hansen BC, Clark A: Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease. J Pathol 179:443-447, 1996
53. Verchere CB, Andrikopoulos S, D'Alessio DA, O'Brien KD, Wight TN, Snow AD, Olin KL, Kahn SE: Role of apolipoprotein E and perlecan in islet amyloid formation in transgenic mice expressing human islet amyloid polypeptide. Diabetes 47 (Suppl. 1):A30, 1998
54. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW: Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 917:148-161, 1987
55. Basu SK, Ho YK, Brown MS, Bilheimer DW, Anderson RG, Goldstein JL: Biochemical and genetic studies of the apoprotein E secreted by mouse macrophages and human monocytes. J Biol Chem 257:9788-9795, 1982
56. Ma J, Yee A, Brewer HB Jr, Das S, Potter H: Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372:92-94, 1994
57. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B: Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145:1030-1035, 1994
58. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, Strittmatter WJ: Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils: isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94:860-869, 1994
59. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17:263-264, 1997
60. Young ID, Ailles L, Narindrasorasak S, Tan R, Kisilevsky R: Localization of the basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type II diabetes mellitus. Arch Pathol Lab Med 116:951-954, 1992
61. Kjellen L, Lindahl U: Proteoglycans: structures and interactions. Annu Rev Biochem 60:443-475, 1991
62. Iozzo RV, Cohen IR, Grassel S, Murdoch AD: The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302:625-639, 1994
63. Fraser PE, Nguyen JT, Chin DT, Kirschner DA: Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J Neurochem 59:1531-1540, 1992
64. Gupta-Bansal R, Frederickson RC, Brunden KR: Proteoglycan-mediated inhibition of A beta proteolysis: a potential cause of senile plaque accumulation. J Biol Chem 270:18666-18671, 1995
65. Castillo GM, Cummings JA, Yang W, Judge ME, Sheardown MJ, Rimvall K, Hansen JB, Snow AD: Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes 47:612-620, 1998
66. Howard CF Jr: Insular amyloidosis and diabetes mellitus in Macaca nigra. Diabetes 27:357-364, 1978
67. Howard CF Jr: Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 29:301-306, 1986
68. Westermark P, Wilander E: The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15:417-421, 1978
69. de Koning EJ, Bodkin NL, Hansen BC, Clark A: Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia 36:378-384, 1993
70. Porte D Jr: β-Cells in type II diabetes mellitus. Diabetes 40:166-180, 1991
71. Cook JT, Patel PP, Clark A, Hoppener JW, Lips CJ, Mosselman S, O'Rahilly S, Page RC, Wainscoat JS, Turner RC: Non-linkage of the islet amyloid polypeptide gene with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34:10:3-108, 1991
72. Nishi M, Bell GI, Steiner DF: Islet amyloid polypeptide (amylin): no evidence of an abnormal precursor sequence in 25 type 2 (non-insulin-dependent) diabetic patients. Diabetologia 33:628-630, 1990
73. Sakagashira S, Sanke T, Hanabusa T, Shimomura H, Ohagi S, Kumagaye KY, Nakajima K, Nanjo K: Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 45:1279-1281, 1996
74. Birch CL, Fagan LJ, Armstrong MJ, Turnbull DM, Walker M: The S20G islet-associated polypeptide gene mutation in familial NIDDM (Letter). Diabetologia 40:1113, 1997
75. Kahn SE, Verchere CB, Andrikopoulos S, Asberry PJ, Leonetti DL, Wahl PW, Boyko EJ, Schwartz RS, Newell-Morris L, Fujimoto WY: Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47:640-645, 1998
76. Westermark G, Benig-Arora M, Fox N, Carroll R, Chan S-J, Westermark P, Steiner DF: Amyloid formation in response to beta cell stress in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. Mol Med 1:542-553, 1995
77. Verchere CB, D'Alessio DA, Kahn SE: Consequences of human islet amyloid polypeptide expression in transgenic mice. In Lessons from Animal Diabetes VI: 75th Anniversary of the Insulin Discovery. Shafrir E, Ed. Boston, Birkhäuser, 1996, p. 131-148
78. Couce M, Kane LA, O'Brien TD, Charlesworth J, Soeller W, McNeish J, Kreutter D, Roche P, Butler PC: Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and B-cell dysfunction. Diabetes 45:1094-1101, 1996
79. vy/a mice expressing human islet amyloid polypeptide. Diabetes 47:743-750, 1998
80. O'Brien TD, Rizza RA, Carney JA, Butler PC: Islet amyloidosis in a patient with chronic massive insulin resistance due to antiinsulin receptor antibodies. J Clin Endocrinol Metab 79:290-282, 1994
81. O'Brien TD, Butler PC, Kreutter DK, Kane LA, Eberhardt NL: Human islet amyloid polypeptide expression in COS-1 cells: a model of intracellular amyloidogenesis. Am J Pathol 147:609-616, 1995
82. de Koning EJP, Morris ER, Hofhuis FM, Posthuma G, Hoppener JW, Morris JF, Capel PJ, Clark A, Verbeek JS: Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A 91:8467-8471, 1994
83. Westermark P, Eizirik DL, Pipeleers DG, Hellerstrom C, Andersson A: Rapid deposition of amyloid in human islets transplanted into nude mice. Diabetologia 38:543-549, 1995
84. Clark A, Edwards CA, Ostle LR, Sutton R, Rothbard JB, Morris JF, Turner RC: Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human B-cells and in islets of type-2 diabetic subjects. Cell Tissue Res 257:179-185, 1989
85. de Koning EJP, Hoppener JWM, Verbeek JS, Oosterwijk C, van Hulst KL, Baker CA, Lips CJM, Morris JF, Clark A: Human islet amyloid polypeptide accumulates at similar sites in islets of transgenic mice and humans. Diabetes 43:640-644, 1994
86. Mulder H, Ahren B, Sundler F: Islet amyloid polypeptide and insulin gene expression are regulated in parallel by glucose in vivo in rats. Am J Physiol 271:E1008-E1014, 1996
87. Johnson KH, O'Brien TD, Jordan K, Westermark P: Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells. Am J Pathol 135:245-250, 1989
88. Pfeifer MA, Halter JB, Judzewitsch RG, Beard JC, Best JD, Ward WK, Porte D Jr: Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man. Diabetes Care 1:25-34, 1984
89. Tokuyania Y, Kanatsuka A, Ohsawa H, Yamaguchi T, Makino H, Yoshida S, Nagase H, Inoue S: Hypersecretion of islet amyloid polypeptide from pancreatic islets of ventromedial hypothalamic-lesioned rats and obese Zucker rats. Endocrinology 128:2739-2744, 1991
90. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr: Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993
91. Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC: Changes in amylin and amylin-like peptide concentrations and β-cell function in response to sulfonylurea or insulin therapy in NIDDM. Diabetes Care 21:810-816, 1998
92. Halban PA, Irminger JC: Sorting and processing of secretory proteins. Biochem J 299:1-18, 1994
93. Nagamatsu S, Nishi M, Steiner DF: Effects of islet amyloid polypeptide (IAPP) on insulin biosynthesis or secretion in rat islets and mouse beta TC3 cells: biosynthesis of IAPP in mouse beta TC3 cells. Diabetes Res Clin Pract 15:49-05, 1992
94. Kahn SE, Verchere CB, D'Alessio DA, Cook DL, Fujimoto WT: Evidence for selective release of rodent islet amyloid polypeptide through the constitutive secretory pathway. Diabetologia 36:570-573, 1993
95. Badman MK, Shennan H, Jermany JL, Docherty K, Clark A: Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 378:227-231, 1996
96. Davidson HW, Rhodes CJ, Hutton JC: Intraorganellar calcium and pH control proinsulin cleavage in the pancreatic β-cell via two distinct site-specific endopeptidases. Nature 333:93-96, 1988
97. Sizonenko S, Irminger JC, Buhler L, Deng S, Morel P, Halban PA: Kinetics of proinsulin conversion in human islets. Diabetes 42:933-9136, 1993
98. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr: Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and experimental insulin resistance. Diabetologia 30:698-702, 1987
99. Kahn SE, Halban PA: Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46:1723-1732, 1987
100. Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE: Human aging is associated with parallel reductions in insulin and amylin release. Am J Physiol 275:E785-E791, 1998
101. McMahon MM, O'Brien PC, Service FJ: Diagnostic interpretation of the intravenous tolbutamide test for insulinoma. Mayo Clin Proc 64:1481-1488, 1989
102. Nagamatsu S, Steiner DF: Altered glucose regulation of insulin biosynthesis in insulinoma cells: mouse beta TC3 cells secrete insulin-related peptides predominantly via a constitutive pathway. Endocrinology 130:748-754, 1992
103. Nagamatsu S, Nishi M, Steiner DF: Biosynthesis of islet amyloid polypeptide. Elevated expression in mouse beta TC3 cells. J Biol Chem 266:13737-13741, 1991
104. Stridsberg M, Wilander E, Oberg K, Lundqvist G, Eriksson B: Islet amyloid polypeptide-producing pancreatic islet cell tumor a clinical and biochemical characterization. Scand J Gastroenterol 27:381-387, 1992
105. Westermark P, Engstrom U, Westermark GT, Johnson KH, Permerth J, Betsholtz C: Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans. Diabetes Res Clin Pract 7:219-226, 1989
106. Tsunehara CH, Leonetti DL, Fujimoto WY: Diet of second-generation Japanese-American men with and without non-insulin-dependent diabetes. Am J Clin Nutr 52:731-738, 1990
107. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN: Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163-1167, 1988
108. Lee SK, Opara EC, Surwit RS, Feinglos MN, Akwari OE: Defective glucose-stimulated insulin release from perifused islets of C57BL/6J mice. Pancreas 11:206-211, 1995
109. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 44:863-870, 1985
110. Shimabukuro M, Zhou YT, Levi M, linger RH: Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 95:2498-2502, 1998
111. Zhou YP, Grill VE: Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest. 93:870-876, 1994
112. Furukawa H, Carroll R, Steiner DF: Long term elevation of free fatty acids leads to delayed processing of proinsulin and prohormone convertases 2 and 3 in the pancreatic beta cell line MIN6. Diabetes 47 (Suppl. 1):A262, 1998
113. Mark RJ, Blanc EM, Mattson MP: Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease. Mol Neurobiol 12:211-224, 1996
114. Bondy SC, Guo-Ross SX, Truong AT: Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res 799:91-96, 1998
115. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW: Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci U S A 90:7951-7955, 1993
116. LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G: The Alzheimer's A beta peptide indures neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 9:21-30, 1995
117. Kapurniotu A, Bemhagen J, Greenfield N, Al-Abed Y, Teichberg S, Frank RW, Voelter W, Bucala R: Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide. Eur J Biochem 251:208-216, 1998
118. Srivastava RA: Regulation of the apolipoprotein E by dietary lipids occurs by transcriptional and post-transcriptional mechanisms. Mol Cell Biochem 155:153-162, 1996
119. Driscoll DM, Mazzone T, Matsushima T, Getz GS: Apoprotein E biosynthesis in the cholesterol-fed guinea pig. Arteriosclerosis 10:31-39, 1990